Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Theriva Biologics Inc. (TOVX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: TOVX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -81.15% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.17M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 26596 | Beta 1.16 | 52 Weeks Range 1.03 - 12.25 | Updated Date 04/1/2025 |
52 Weeks Range 1.03 - 12.25 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -19.03 |
Earnings Date
Report Date 2025-03-24 | When Before Market | Estimate -7.22 | Actual -11.49 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -25.85% | Return on Equity (TTM) -87.31% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -6983307 | Price to Sales(TTM) - |
Enterprise Value -6983307 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.72 | Shares Outstanding 2782450 | Shares Floating 2398276 |
Shares Outstanding 2782450 | Shares Floating 2398276 | ||
Percent Insiders 8.56 | Percent Institutions 16.36 |
Analyst Ratings
Rating 4.5 | Target Price 90.5 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Theriva Biologics Inc.
Company Overview
History and Background
Theriva Biologics, Inc. (formerly Synthetic Biologics, Inc.) is a clinical-stage biopharmaceutical company focused on developing novel therapies to treat diseases associated with the human microbiome. Founded in 2011, the company has evolved from a focus on infectious diseases to microbiome-related therapies.
Core Business Areas
- Veraplasmid: Veraplasmid is Theriva's lead investigational therapy for the treatment of Acute Lymphoblastic Leukemia. It is a gene therapy designed to deliver a potent anti-cancer gene directly to cancer cells.
- SYN-020 Intestinal Alkaline Phosphatase (IAP) oral formulation: SYN-020 is an oral formulation of Intestinal Alkaline Phosphatase, a naturally occurring enzyme in the small intestine to treat diseases.
Leadership and Structure
The leadership team consists of seasoned professionals in the biotech and pharmaceutical industries. The organizational structure typically involves departments for research and development, clinical operations, regulatory affairs, and business development. Details of the structure are described at https://www.therivabio.com/leadership
Top Products and Market Share
Key Offerings
- Veraplasmid: Veraplasmid is a gene therapy product candidate designed to treat Acute Lymphoblastic Leukemia (ALL). This product is still in clinical trials. Competitors include pharmaceutical companies developing similar gene therapies for ALL.
- SYN-020 Intestinal Alkaline Phosphatase (IAP) oral formulation: SYN-020 is designed to treat diseases. This product is still in clinical trials. Competitors include pharmaceutical companies developing similar therapies
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense competition, high research and development costs, and stringent regulatory requirements. Advances in biotechnology are driving innovation in areas such as gene therapy and microbiome-based therapeutics.
Positioning
Theriva Biologics is positioned as a clinical-stage biopharmaceutical company focused on innovative therapies targeting unmet medical needs. Its competitive advantage lies in its unique technology platforms and pipeline of novel drug candidates.
Total Addressable Market (TAM)
The Total Addressable Market is highly variable and is dependent on the indication being targeted, and can range from several hundred million to several billion USD, depending on the specific market. Theriva Biologics is positioned to serve the global population.
Upturn SWOT Analysis
Strengths
- Novel technology platforms
- Pipeline of innovative drug candidates
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Limited financial resources
- Dependence on clinical trial outcomes
- Lack of marketed products
- High cash burn rate
Opportunities
- Strategic collaborations and partnerships
- Expansion of the pipeline through acquisitions or in-licensing
- Advancement of drug candidates to later-stage clinical trials
- Positive clinical trial data leading to regulatory approval
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from larger pharmaceutical companies
- Economic downturn affecting financing
Competitors and Market Share
Key Competitors
- LLY
- MRK
- PFE
Competitive Landscape
Theriva Biologics competes with larger pharmaceutical companies in the development of microbiome-based therapies and gene therapies. Its competitive advantage lies in its innovative technology platforms and focus on specific unmet medical needs.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Theriva Biologics' growth has been driven by the advancement of its drug candidates through clinical development.
Future Projections: Future growth is contingent on successful clinical trial outcomes, regulatory approvals, and commercialization efforts. Analyst projections are available.
Recent Initiatives: Recent initiatives include initiating new clinical trials, forming strategic partnerships, and seeking funding.
Summary
Theriva Biologics is a pre-revenue clinical-stage biopharmaceutical company with promising technology platforms. The company faces significant risks related to clinical trials and regulatory approvals. Its strengths are in its novel drug candidates and experienced management, while weaknesses include limited financial resources. Success hinges on positive clinical trial data and strategic partnerships.
Similar Companies
- LLY
- MRK
- PFE
Sources and Disclaimers
Data Sources:
- Theriva Biologics Inc. Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Theriva Biologics Inc.
Exchange NYSE MKT | Headquaters Rockville, MD, United States | ||
IPO Launch date 2006-12-18 | CEO, CFO, Treasurer, Corporate Secretary & Director Mr. Steven A. Shallcross CPA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 20 | Website https://therivabio.com |
Full time employees 20 | Website https://therivabio.com | ||
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d'Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.